CenExel Clinical Research Acquires California Neuroscience Research

BayPine to Acquire CenExel Clinical Research

April 14, 2025

Healthcare Services

BayPine entered into a definitive agreement to acquire CenExel Clinical Research, a nationwide clinical trial site network focused on complex therapeutic areas. After closing, BayPine will be the majority investor in CenExel alongside Webster Equity Partners, which will retain a minority stake, with management continuing to hold equity.

CenExel Acquires Apex Innovative Sciences from Bison Capital

June 16, 2022

Healthcare Services

CenExel Clinical Research has acquired Apex Innovative Sciences, Inc. from Bison Capital Partners V, LP. The transaction adds Apex’s CNS-focused clinical research sites (including Collaborative Neuroscience Research and Hassman Research Institute) — five centers across California and New Jersey with substantial early‑phase and inpatient capacity — expanding CenExel’s neuroscience capabilities and geographic footprint.

CenExel Acquires iResearch

May 3, 2022

Healthcare Services

CenExel, a Salt Lake City–based clinical research site network, acquired iResearch, a multi-specialty clinical research site with locations in Decatur and Savannah, Georgia. The deal strengthens CenExel's CNS (psychiatry and neurology) and dermatology trial capabilities while expanding its patient reach in the Atlanta metro and throughout Georgia.

CenExel Clinical Research Acquires CTSdatabase

February 22, 2022

Healthcare Services

CenExel Clinical Research has acquired CTSdatabase, a global duplicate-subject detection and clinical trial registry led by Dr. Thomas M. Shiovitz. The acquisition integrates CTSdatabase's subject-detection capabilities into CenExel's site network to improve data quality across clinical trials while CTSdatabase will continue to operate independently and support external sponsors and CROs.

CenExel Clinical Research Acquires Rocky Mountain Movement Disorders Center

January 11, 2022

Healthcare Services

CenExel Clinical Research, Inc. acquired the clinical research site operations of Rocky Mountain Movement Disorders Center (now CenExel RMCR), expanding CenExel's neurology/CNS trial capabilities and site network. Objective, Investment Banking & Valuation acted as exclusive sell-side advisor to Rocky Mountain Movement Disorders Center and the transaction will allow the center to leverage CenExel's centralized processes and network.

CenExel Clinical Research Acquires CITrials

March 9, 2021

Healthcare Services

CenExel Clinical Research, a U.S.-based network of clinical research sites, has acquired CITrials, a Southern California clinical research firm operating three sites serving Los Angeles, Orange, and Riverside/San Bernardino counties. The acquisition expands CenExel's capacity and capabilities in psychiatric and neurological (CNS) research and enables greater integration with its other Southern California operations.